EG384244 Inhibitors
EG384244 inhibitors refer to a class of chemical compounds that are specifically designed to interact with and inhibit the activity of a biological target, often at a molecular level. The structure of EG384244 inhibitors typically involves a core scaffold that binds selectively to its target, providing strong affinity and specificity. This binding action interferes with the biological function of the target, leading to an alteration in its normal activity. The core structures of these inhibitors often include diverse chemical moieties that allow for the fine-tuning of their interaction with the target, enhancing their potency, stability, and selectivity. They may feature functional groups that enable hydrogen bonding, hydrophobic interactions, and van der Waals forces, which are essential for their inhibitory action. Furthermore, the design of these inhibitors is usually guided by structure-activity relationship (SAR) studies, which allow for the optimization of their biochemical properties.
The development of EG384244 inhibitors requires a precise understanding of their target's structure, binding sites, and the molecular mechanisms governing their activity. Chemically, these inhibitors can vary significantly in size and complexity, ranging from small organic molecules to more complex structures with multiple ring systems, heteroatoms, and side chains designed to enhance their binding and physicochemical properties. Their synthesis often involves a variety of organic reactions aimed at constructing the desired scaffold and adding functional groups that contribute to binding efficiency and metabolic stability. These inhibitors are typically evaluated in vitro for their potency and specificity, and chemical modifications are made iteratively to enhance their efficacy. Overall, EG384244 inhibitors serve as tools for modulating biological pathways and are a result of intricate chemical design aimed at precise molecular interactions with their intended target.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
DNA transcription inhibitor binding to RNA polymerase. Actinomycin D directly inhibits Foxl3 by preventing RNA polymerase II-mediated transcription, disrupting its ability to bind specific DNA sequences within cis-regulatory regions. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
RNA polymerase II inhibitor affecting transcription. Alpha-Amanitin directly inhibits Foxl3 by targeting RNA polymerase II, leading to a specific block in RNA synthesis and negatively impacting DNA-binding transcription factor activity. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Inhibitor of transcriptional elongation. Triptolide directly inhibits Foxl3 by suppressing RNA polymerase II elongation, disrupting its ability to bind cis-regulatory regions and exerting negative regulation on transcription by RNA polymerase II. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
Selective RNA polymerase I inhibitor. CX-5461 indirectly inhibits Foxl3 by disrupting ribosomal RNA synthesis, potentially impacting RNA polymerase II-specific DNA binding and leading to negative regulation of transcription within cis-regulatory regions. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
CDK inhibitor affecting transcription. Flavopiridol directly inhibits Foxl3 by targeting CDKs, crucial for RNA polymerase II activity, potentially affecting its DNA-binding transcription factor function and negative regulation of transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibitor of transcription elongation. DRB directly inhibits Foxl3 by impeding RNA polymerase II elongation, hindering its interaction with cis-regulatory regions and leading to negative regulation of transcription by RNA polymerase II. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
p300/CBP inhibitor affecting transcription. C646 directly inhibits Foxl3 by targeting p300/CBP, modulating its coactivator function in RNA polymerase II-mediated transcription and potentially disrupting DNA-binding transcription factor activity. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Nucleoside analog inhibiting RNA polymerase II. Fludarabine directly inhibits Foxl3 by incorporating into RNA, disrupting RNA polymerase II activity, and negatively impacting DNA-binding transcription factor function within cis-regulatory regions. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Topoisomerase II inhibitor affecting DNA structure. Etoposide directly inhibits Foxl3 by inducing DNA damage and altering chromatin structure, potentially disrupting its DNA-binding transcription factor activity within cis-regulatory regions. | ||||||